-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Gossamer Bio, Lowers Price Target to $3

Benzinga·03/05/2026 17:53:12
Listen to the news
Oppenheimer analyst Andreas Argyrides maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $12 to $3.